PRMT Inhibitors

In recent years, the role of epigenetics in tumor initiation and progression has attracted extensive attention. In addition to genetic mutations, epigenetic alterations and post-translational modifications have been demonstrated to play crucial roles in cancer development and maintenance. Among these, protein arginine methyltransferases (PRMTs) represent an important family of epigenetic regulators that catalyze the methylation of arginine residues, thereby modulating gene expression, protein function, signal transduction, and cell cycle progression. To date, nine PRMT isoforms have been identified and are classified into three types based on their catalytic products: Type I PRMTs (e.g., PRMT1, PRMT4, PRMT6) generate asymmetric dimethylarginine (ADMA); Type II PRMTs (e.g., PRMT5, PRMT9) produce symmetric dimethylarginine (SDMA); and Type III PRMTs (e.g., PRMT7) catalyze monomethylarginine (MMA) formation. These enzymes act on both histone and non-histone substrates, establishing a complex regulatory network that integrates multiple cellular processes. Accumulating evidence indicates that PRMTs are overexpressed in various human cancers, including melanoma, multiple myeloma, glioblastoma, lung cancer, urothelial carcinoma of the bladder, gastric, cervical, ovarian, and colorectal cancers, and their dysregulation is closely associated with poor patient prognosis. Consequently, targeting PRMTs has emerged as a promising strategy for anticancer therapy. Notably, the biological effects of PRMT inhibition extend beyond chromatin regulation to RNA processing and immune signaling, providing unique therapeutic advantages and potential biomarker opportunities. Several PRMT inhibitors have demonstrated potent antitumor efficacy in preclinical and clinical studies. In the future, PRMT-targeted therapy is expected to be combined with DNMT, HDAC, or BET inhibitors, as well as DNA damage response modulators and immunotherapies, to achieve synergistic therapeutic outcomes. Collectively, PRMTs represent novel and compelling therapeutic targets with significant research and clinical potential in cancer treatment.

PRMT Inhibitors

GSK3326595
click to sign in and save

A4168401616392-22-398%

GSK3326595

$160.00/100mg Detail

AMI-1
click to sign in and save

A20167320324-87-299%

AMI-1

$62.00/50mg Detail

GSK591
click to sign in and save

A1129921616391-87-799%

GSK591

$27.00/5mg Detail

TC-E 5003
click to sign in and save

A16954917328-16-497%

TC-E 5003

$88.00/100mg Detail

EPZ015666
click to sign in and save

A2727701616391-65-198%

EPZ015666

$483.00/100mg Detail

LLY-283
click to sign in and save

A6724442040291-27-699%

LLY-283

$55.00/1mg Detail

AMG-193
click to sign in and save

A20043372790567-82-599%

AMG-193

$154.00/10mg Detail

MRTX-1719
click to sign in and save

A15403512630904-45-798%

MRTX-1719

$159.00/10mg Detail

EPZ020411 HCl
click to sign in and save

A9499072070015-25-599%

EPZ020411 HCl

$158.00/10mg Detail

MS049
click to sign in and save

A5675341502816-23-098%

MS049

$143.00/50mg Detail

HLCL-61 HCl
click to sign in and save

A7208331158279-20-999%

HLCL-61 HCl

$10.00/1mg Detail

MS023
click to sign in and save

A6042251831110-54-398%

MS023

$107.00/10mg Detail

PRMT5-IN-20
click to sign in and save

A1671122880813-30-999%

PRMT5-IN-20

$96.00/10mg Detail

SGC2085
click to sign in and save

A1496361821908-48-898%

SGC2085

$547.00/25mg Detail

TP-064
click to sign in and save

A8961582080306-20-198%

TP-064

$316.00/50mg Detail

XY1
click to sign in and save

A1551701624117-53-899%

XY1

$62.00/10mg Detail

UNC0646
click to sign in and save

A8806771320288-17-298%

UNC0646

$52.00/5mg Detail

UNC0224
click to sign in and save

A5965991197196-48-798%

UNC0224

$362.00/50mg Detail

SGC707
click to sign in and save

A1656571687736-54-498+%

SGC707

$104.00/50mg Detail

MRTX9768
click to sign in and save

A15473112629314-68-595%

MRTX9768

$137.00/1mg Detail

1 2    page 1 of 2 Pages